Viva Biotech Holdings (FRA:VB0) Asset Turnover: 0.13 (As of Dec. 2025)


FRA:VB0 Viva Biotech Holdings FRA:VB0
47 GF Score
Price €0.12
GF Value €0.08
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Viva Biotech Holdings Asset Turnover?

Viva Biotech Holdings FRA:VB0 +2.59% 47 Asset Turnover is 0.13 as of Dec. 2025. GuruFocus rates FRA:VB0 with a GF Score™ of 47/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Viva Biotech Holdings's Revenue for the six months ended in Dec. 2025 was €108.8 Mil. Viva Biotech Holdings's Total Assets for the quarter that ended in Dec. 2025 was €852.0 Mil. Therefore, Viva Biotech Holdings's Asset Turnover for the quarter that ended in Dec. 2025 was 0.13.

Asset Turnover is linked to ROE % through Du Pont Formula. Viva Biotech Holdings's annualized ROE % for the quarter that ended in Dec. 2025 was 4.98%. It is also linked to ROA % through Du Pont Formula. Viva Biotech Holdings's annualized ROA % for the quarter that ended in Dec. 2025 was 2.79%.

Viva Biotech Holdings  (FRA:VB0) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Viva Biotech Holdings's annulized ROE % for the quarter that ended in Dec. 2025 is

ROE %**(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=23.754/477.3145
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(23.754 / 217.664)*(217.664 / 851.996)*(851.996/ 477.3145)
=Net Margin %*Asset Turnover*Equity Multiplier
=10.91 %*0.2555*1.785
=ROA %*Equity Multiplier
=2.79 %*1.785
=4.98 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Viva Biotech Holdings's annulized ROA % for the quarter that ended in Dec. 2025 is

ROA %(Q: Dec. 2025 )
=Net Income/Total Assets
=23.754/851.996
=(Net Income / Revenue)*(Revenue / Total Assets)
=(23.754 / 217.664)*(217.664 / 851.996)
=Net Margin %*Asset Turnover
=10.91 %*0.2555
=2.79 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.

Viva Biotech Holdings Asset Turnover Related Terms

Viva Biotech Holdings Asset Turnover Historical Data

* Premium members only.

The historical data trend for Viva Biotech Holdings's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viva Biotech Holdings Asset Turnover Chart

Viva Biotech Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 0.29 0.27 0.28 0.23

Viva Biotech Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.13 0.14 0.11 0.13

FRA:VB0 vs VRTX, REGN, ALNY: Asset Turnover Comparison

For the Biotechnology subindustry, Viva Biotech Holdings's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viva Biotech Holdings Asset Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Viva Biotech Holdings's Asset Turnover falls into.


FRA:VB0
47GF Score
Viva Biotech Holdings FRA:VB0
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viva Biotech Holdings Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Viva Biotech Holdings's Asset Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=209.698/( (924.817+872.917)/ 2 )
=209.698/898.867
=0.23

Viva Biotech Holdings's Asset Turnover for the quarter that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=108.832/( (831.075+872.917)/ 2 )
=108.832/851.996
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.13 mean?
Viva Biotech Holdings (FRA:VB0) has a Asset Turnover of 0.13 as of Dec. 2025. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Viva Biotech Holdings and its competitors.
Is Viva Biotech Holdings' Asset Turnover too high?
Viva Biotech Holdings' current Asset Turnover is 0.13. Overall, Viva Biotech Holdings has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' Asset Turnover compare to VRTX and REGN?
Viva Biotech Holdings' Asset Turnover of 0.13 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Biotechnology company?
A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Viva Biotech Holdings and its competitors. Viva Biotech Holdings's current Asset Turnover is 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.12 — trading 48.8% above its estimated fair value. The current Asset Turnover is 0.13. Viva Biotech Holdings' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current Asset Turnover is 0.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?

Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued. The current stock price of €0.12 is trading 48.8% above its estimated GF Value™ of €0.08. GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.

Key valuation signals for FRA:VB0:

  • Asset Turnover: 0.13
  • GF Value™: €0.08 vs. price of €0.12 (48.8% above fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viva Biotech Holdings Business Description

Other Exchanges VBIZF:USA01873:Hong Kong
Address 735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
47GF Score

Get the complete analysis for FRA:VB0

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.12
Price
€0.08
GF Value